Literature DB >> 10362117

Growth dysregulation and p53 accumulation in human primary colorectal cancer.

D S Watson1, I Brotherick, B K Shenton, R G Wilson, F C Campbell.   

Abstract

p53 accumulation is common in colorectal cancer, but effects on growth homeostasis are unclear. In this study, DNA content, cell cycle phase fractions and DNA strand-breaks consistent with apoptosis were assessed by flow cytometry in 42 fresh primary colorectal tumours and matched normal mucosa. p53 accumulation was assessed in 37 fixed tumour sections, by immunohistochemistry. In normal mucosa, 10.3 +/- 6.6% (mean +/- s.d.) cells were in DNA synthesis phase while 28.7 +/- 17.9% showed apoptosis. A relationship suggestive of growth homeostasis, was observed between these parameters (r = 0.8; P < 0.05). In cancers, a greater number of cells were in DNA synthesis phase (15.6 +/- 12.9% tumour vs mucosa 10.3 +/- 6.6%; P < 0.02) while fewer showed apoptosis than normal mucosa (18.5 +/- 17.0% tumour vs mucosa 28.7 +/- 17.9%; P < 0.01). DNA synthesis and apoptosis fractions were unrelated in cancers, suggesting growth dysequilibrium. p53 accumulation was detected in 59% (22/37) tumours and was associated with reduced apoptosis compared to p53-negative tumours or mucosa (14.8 +/- 15% p53 accumulation vs 26.3 +/- 18% p53-negative; P < 0.05; vs 28.7 +/- 17.9% mucosa; P < 0.05). p53 accumulation was unrelated to DNA synthesis phase fractions. p53 accumulation is accompanied by reduced apoptosis which may accentuate growth dysequilibrium in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10362117      PMCID: PMC2363047          DOI: 10.1038/sj.bjc.6690464

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication.

Authors:  J Bargonetti; P N Friedman; S E Kern; B Vogelstein; C Prives
Journal:  Cell       Date:  1991-06-14       Impact factor: 41.582

2.  Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line.

Authors:  P Shaw; R Bovey; S Tardy; R Sahli; B Sordat; J Costa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

3.  Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization.

Authors:  F Z Bischoff; S O Yim; S Pathak; G Grant; M J Siciliano; B C Giovanella; L C Strong; M A Tainsky
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

4.  The clonal evolution of tumor cell populations.

Authors:  P C Nowell
Journal:  Science       Date:  1976-10-01       Impact factor: 47.728

5.  p53 expression in colorectal tumors.

Authors:  C A Purdie; J O'Grady; J Piris; A H Wyllie; C C Bird
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

6.  Suppression of human colorectal carcinoma cell growth by wild-type p53.

Authors:  S J Baker; S Markowitz; E R Fearon; J K Willson; B Vogelstein
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

Review 7.  Cytometric DNA analysis in the management of cancer. Clinical and laboratory considerations.

Authors:  C J Herman
Journal:  Cancer       Date:  1992-03-15       Impact factor: 6.860

8.  Participation of p53 protein in the cellular response to DNA damage.

Authors:  M B Kastan; O Onyekwere; D Sidransky; B Vogelstein; R W Craig
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

9.  Why is p53 protein stabilized in neoplasia? Some answers but many more questions?

Authors:  V Save; K Nylander; P A Hall
Journal:  J Pathol       Date:  1998-04       Impact factor: 7.996

10.  p53 in colorectal cancer: clinicopathological correlation and prognostic significance.

Authors:  N Scott; P Sagar; J Stewart; G E Blair; M F Dixon; P Quirke
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

View more
  2 in total

1.  Connexin 26 correlates with Bcl-xL and Bax proteins expression in colorectal cancer.

Authors:  Luiza Kanczuga-Koda; Stanislaw Sulkowski; Mariusz Koda; Elzbieta Skrzydlewska; Mariola Sulkowska
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

2.  In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer.

Authors:  Premila D Leiphrakpam; Ekta Agarwal; Michelle Mathiesen; Katie L Haferbier; Michael G Brattain; Sanjib Chowdhury
Journal:  Oncol Rep       Date:  2013-10-25       Impact factor: 3.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.